← SynDRA
MELPHALAN
SynDRA canonical compound SYN0002219 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Mechanism of action | DNA alkylating agent | DNA inhibitor |
|---|
| Indication | multiple myeloma |
|---|
| Disease area | hematologic malignancy |
|---|
All known targets
Mechanisms of action (all sources)
- DNA alkylating agent
- DNA inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ABCB11
- HIF1A
- OPRK1
- OPRD1
- NR3C1
- NR1H4
- NPY2R
- NPY1R
- NFE2L2
- MMP9
- MMP1
- MC5R
- MC4R
- MC3R
- MAPK3
- MAPK14
- MAPK1
- MAOA
- LCK
- KDR
- KCNH2
- HTR6
- HTR2C
- HTR2B
- HTR2A
- HTR1A
- HRH3
- HRH2
- HRH1
- OPRM1
- PDE3A
- PDE4A
- SLC6A3
- VDR
- USP1
- TP53
- TDP1
- TBXAS1
- TBXA2R
- TARDBP
Drug classes
- Alkylating Activity
- Alkylating Drug
- Alkylating Agents
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Immunologic Factors
- Immunosuppressive Agents
- Myeloablative Agonists
- Noxae
ATC classes
Cross-references
Synonyms
- ALKERAN
- EVOMELA
- Evomela
- HEPZATO
- Hepzato
- IVRA
- Ivra
- MELPHALAN HYDROCHLORIDE
- melphalan hydrochloride
- alkeran
- levofalan
- levofolan
- levopholan
- melfalan
- phenylalanine mustard
- sarcoclorin
- melphalan HCl
- Melfalan
- Alanine nitrogen mustard
- L-pam
- L-phenylalanine mustard
- L-sarcolysin
- Phenylalanine mustard
- Sarcolycin, l-
- CB-3025
- NCI-C04853
- NSC-241286
- NSC-8806
- SK-15673
- Alkeran
- Levofalan
- Levofolan
- Levopholan
- Melfalano
- Melphalanum
- Alanine Nitrogen Mustard
- Phenylalanine nitrogen mu stard
- Phenylalanine nitrogen mustard
Reported adverse events
- Hypersensitivity
- Hypersensitivity reaction
- Myelosuppression
- Cardiac arrest
- Injection
- Dizziness
- Fatigue
- Nausea
- Pyrexia
- Vomiting
- Activated partial thromboplastin time
- Activated partial thromboplastin time prolonged
Look up MELPHALAN in the interactive SynDRA portal →